ABSTRACT PURPOSE: To determine whether the use of topical apraclonidine just before the LASIK procedure prevents subconjunctival hemorrhage and to study its effect on postoperative fl ap adherence.
METHODS: Topical apraclonidine 0.125% was randomly applied to 1 eye of 66 myopic patients who underwent primary bilateral LASIK. Apraclonidine was instilled 1 hour prior to and 30 seconds just before placing the vacuum ring of the microkeratome, whereas the other eye served as control. Thirty minutes after the operation, all patients were examined by the surgeon to evaluate hyperemia and identify fl ap-related complications (eg, slippage, dislocation, or fl ap folds). The size of subconjunctival hemorrhage was also evaluated on postoperative days 1 and 7. All 132 eyes in the study were examined after surgery to identify fl ap folds and/or their dislocation.
RESULTS:
In the apraclonidine group, 48 (72.8%) eyes had no hyperemia, 16 (24.2%) eyes had mild hyperemia, 2 (3%) eyes had moderate hyperemia, and no (0%) eyes had severe hyperemia. In the control group, 37 (56.1%) eyes had mild hyperemia, 21 (31.8%) eyes had moderate hyperemia, 1 (1.5%) eye had severe hyperemia, and 7 (10.6%) eyes had no hyperemia. In the apraclonidine group, 44 (66.7%) eyes had no subconjunctival hemorrhage (grade 0); grade 1 was present in 19 (28.8%) eyes whereas grades 2 and 3 were present in 2 (3%) eyes and 1 (1.5%) eye, respectively. In the control group, 19 (28.8%) eyes showed grade 0, 13 (19.7%) eyes had grade 1, and grades 2 and 3 were present in 20 (30.3%) eyes and 14 (21.2%) eyes, respectively. Chi-square test showed a highly signifi cant difference between the two groups (PϽ.001). No fl aprelated problems were reported in either group. L aser in situ keratomileusis (LASIK) is a popular and relatively safe surgical procedure for the correction of myopia, hyperopia, and astigmatism. 1 Although medical reasons are involved, many patients who seek LASIK surgery would like to free themselves from their glasses or contact lenses due to practical or cosmetic reasons. Thus, they want to see well from the fi rst postoperative day. However, a number of patients have postoperative hyperemia and subconjunctival hemorrhage [2] [3] [4] due to surgical manipulation, mainly because of the use of a vacuum ring during fl ap creation. Although postoperative subconjunctival hemorrhage is considered to be a temporary cosmetic problem, a signifi cant degree of unnecessary anxiety and false alarm may arise in some patients in the immediate postoperative days.
Apart from its well-described function among anti-glaucoma drugs, 5 topical apraclonidine applied just before LASIK surgery may cause vasoconstriction 5 of conjunctival vessels and thus reduce the occurrence and severity of subconjunctival hemorrhage, as described with another vasoconstrictor, brominidine. 6, 7 Proper adhesion between the corneal fl ap and stromal bed is mandatory after LASIK surgery to properly restore the corneal integrity, promote normal healing, and establish an adequate refractive outcome. Several fl ap complications that occur from poor fl ap adherence have been described, 2, 3 and there is controversial evidence that use of the vasoconstrictor brimonidine may increase the incidence of such complications. 7 The aim of this study is to study the effectiveness of topical apraclonidine on decreasing conjunctival hyperemia and subconjunctival hemorrhage and its potential infl uence on fl ap adherence after LASIK surgery. All procedures were performed by the same surgeon (I.M.A.), using an identical technique in all eyes regarding preoperative medication, use of microkeratome, fl ap manipulation, and drying time. The details of the technique are as follows: one drop of proparacaine 0.5% (Alcaine; Alcon, Ft Worth, Tex) was instilled into each eye and the upper and lower lids were cleaned with povidone-iodine (Betadine). One additional drop of proparacaine was added to the operative eye immediately prior to the procedure. A drape was used to retract the eyelashes, and a speculum was placed into the operative eye, while the fellow eye was occluded with an eye shield. Methylene blue (Visimark; Becton Dickinson & Co, Franklin Lakes, NJ) was used to mark the cornea in preparation for making the lamellar fl ap. A Moria M2 microkeratome (Moria Surgical, Antony, France) was used in manual mode to make a superiorly hinged fl ap in all 132 eyes. After the fl ap was made, the conjunctival fornix was dried using a surgical sponge (Murocel; Medtronic Solan, Jacksonville, Fla). The fl ap was retracted back using a double-barrelled LASIK cannula (Moria Surgical). After laser ablation with the ALLEGRETTO WAVE excimer laser (WaveLight Laser Technologie AG, Erlangen, Germany), the fl ap was fl oated back into position with minimal irrigation of balanced salt solution (BSS, Alcon) using the aforementioned cannula. A dry Murocel sponge was then used to absorb the excessive moisture from beneath the fl ap, dry the periphery of the fl ap, and ensure a symmetric fl ap gutter. Subsequently, a wet sponge was used to smooth the fl ap and ensure its proper alignment with no visible folds. All fl aps were allowed to dry for 1.5 minutes. The symmetry of the gutter was further evaluated by instilling a chalk white drop of prednisolone acetate (Pred Forte; Allergan Pharmaceuticals Ltd, Westport, County Mayo, Ireland), which clearly demarcated the exact outline of the gutter. A striae test was performed to ensure proper fl ap adherence by pressing the cornea just outside of the fl ap edge with a Murocel sponge to check whether striae outside the fl ap are in continuation with those inside the fl ap. All eyes were examined within 15 minutes after surgery. Patients were instructed to keep their eyes lightly closed, to wear protective eye shields at night, and return the following day for re-examination.
PATIENTS AND METHODS
In addition to the previously described standard technique, a drop of 0.125% topical apraclonidine was applied randomly (with a fl ip of a coin) to one eye of each patient 1 hour prior to and 30 seconds just before placing the vacuum ring of the microkeratome. In the control eye, a drop of sodium hyaluronate 0.18% (Vismed; TRB Chemedica, Greece) was instilled.
Thirty minutes postoperatively, severity of hyperemia of both eyes was detected by an independent observer (N.T.) in a double-blind manner and classifi ed as follows: grade 0, no hyperemia; grade 1, mild; grade 2, moderate, and grade 3, severe. The size of subconjunctival hemorrhage was detected on the fi rst postoperative day. The size of the subconjunctival hemorrhage was classifi ed by slit-lamp examination as follows: grade 0, no hemorrhage present; grade 1, Ͻ1 mm (micro-hemorrhage); grade 2, between 1 and 3 mm (moderate hemorrhage); and grade 3, Ͼ3 mm (macrohemorrhage).
The appearance of the fl ap with respect to folds and dislocations was carefully monitored using slit-lamp microscopy immediately after (Ͻ15 minutes) and on the day after the surgery (24 hours). Folds were defi ned as a series of parallel ridges in the fl ap that were best seen with retro-illumination and stained negatively with fl uorescein. A dislocation was defi ned as folds accompanied by у0.5-mm displacement of the fl ap edge from the edge of the lamellar cut.
Postoperatively, patients were prescribed sodium fl urbiprofen 0.03% (Ocufl ur, Allergan) drops 4 times a day for 2 days, dexamethasone 0.1% and tobramycin 0.3% (Tobradex, Alcon) drops 4 times a day for 2 weeks, and Vismed drops initially hourly and then when necessary for 1 month thereafter.
Statistical analysis was performed using a chi-square test, and PϽ.01 was considered statistically signifi cant. For this statistical test, the expected frequency could not be Ͻ5 in Ͼ20% of cells, 8 therefore the values for moderate and severe hyperemia were combined for the purpose of statistical evaluation.
RESULTS

VASOCONSTRICTIVE EFFECTS
In the apraclonidine group, 48 (72.8%) eyes had no hyperemia, 16 (24.2%) eyes had mild hyperemia, and 2 eyes (3%) had moderate hyperemia. No eye had severe hyperemia. In the control group, 37 (56.1%) eyes had mild, 21 (31.8%) eyes moderate, and 1 (1.5%) eye had severe hyperemia. Seven (10.6%) eyes did not have any hyperemia (Fig 1) . Chi-square test revealed a signifi cant difference between the two groups (PϽ.001).
Concerning the subconjunctival hemorrhage, in the apraclonidine group, 44 (66.7%) eyes had no subconjunctival hemorrhage (grade 0), and grade 1 was present in 19 (28.8%) eyes, whereas grades 2 and 3 were present in 2 (3%) eyes and in 1 (1.5%) eye, respectively. In the control group, 19 (28.8%) eyes were grade 0, 13 (19.7%) eyes were grade, and grades 2 and 3 were present in 20 (30.3%) eyes and 14 (21.2%) eyes, respectively (Fig 2) . A signifi cant difference was noted between the two groups using the chi-square test (PϽ.001).
FLAP ADHERENCE AND OTHER EFFECTS
No eye had any fl ap complications in the postoperative course, including fl ap adherence problems. All eyes in the apraclonidine group had a slight upper eyelid retraction, which was not present the following day.
DISCUSSION
Although LASIK is sometimes performed for medical reasons (eg, correction of anisometropia), it is performed mostly for cosmetic purposes. After LASIK surgery, most patients experience subconjunctival hemorrhage due to surgical manipulation and the use of the vacuum ring during fl ap creation. Because it is a self-limited and temporary complication, most surgeons do not consider subconjunctival hemorrhage a problem. Many patients, however, despite prior counseling, perceive this as an untoward effect rather than just a cosmetic problem. Patients may be alarmed and worried about the surgical outcome, although it usually resolves spontaneously within 2 to 3 weeks; this condition may persist even longer in some cases.
Topical apraclonidine has a vasoconstrictive 5 effect due to its alpha-mimetic action and is used for glaucoma treatment. Vajpayee et al 9 determined that interface hemorrhage during LASIK surgery may affect visual performance. Topical apraclonidine may prevent interface hemorrhage and therefore prevent its possible deteriorative effect on postoperative course and visual outcome. Before LASIK, instillation of one drop of apraclonidine may prevent hyperemia and subconjunctival hemorrhage by its vasoconstrictive effect on conjunctival vessels.
Topical apraclonidine also has an ocular hypo- tensive effect and is used in glaucoma treatment as 0.125% to 0.5% drops due to its partial agonistic effect on alpha-2 adrenergic receptors. As more speculations arise from glaucoma specialists about potential barotrauma damage on the optic nerve head during suction in LASIK surgery, apraclonidine might add more in our everyday surgical routine. Because the perfusion pressure equals the systemic blood pressure minus the intraocular pressure (IOP), when apraclonidine is applied just 30 seconds before LASIK surgery, its vasoconstrictive effect begins prior to vacuum ring application. However, as its antiglaucomatous effect does not take place until 1 hour later with the peak at 3 to 5 hours, 5 one drop was also applied 1 hour prior to the surgery. This has another potentially benefi cial effect on the eye, as it may decrease the risk of post-traumatic IOP peak (barotrauma) after the surgery. McCarty et al, 10 on the other hand, found that the use of brimonidine prior to LASIK did not affect the structure or function of the optic nerve, and that the alteration in corneal birefringence after excimer laser ablation may explain the reduction in direct retinal nerve fi ber layer measures without the concomitant change in ratio measures. However, as this surpasses the scope of our paper, we suggest further clinical studies focusing on the numerous variables involved in the optic nerve head perfusion be carried out to clarify this hypothesis.
Norden 6 conducted a double-masked study and concluded that topical brimonidine before LASIK surgery may decrease the amount of subconjunctival hemorrhage and hyperemia due to LASIK surgery. Our study confi rms the hypothesis that alpha-agonists applied topically, in our case apraclonidine, may signifi cantly decrease hyperemia and subconjunctival hemorrhage after LASIK surgery.
In all cases, eyes treated with apraclonidine had upper lid retraction in the early postoperative period due to stimulation of the upper lid Muller muscle by the alpha-mimetic action of apraclonidine. Left eyes in which apraclonidine was applied had upper lid retraction and less hyperemia; however, right eyes without apraclonidine had relatively ptotic and more hyperemic appearance. The difference in appearance revealed signifi cant cosmetic disparity between the two eyes.
Topical apraclonidine may lead to ocular and dermatologic allergic reactions 5 in chronic use as in glaucoma treatment. Therefore, it should not be used for a long period of time to prevent hyperemia otherwise rebound effect may occur. 5 In this study, we did not detect any allergic reaction due to topical apraclonidine. This may be due to the single use of the drug.
Walter et al 7 concluded that topical brimonidine application before LASIK surgery may lead to an increase in abnormal fl ap adhesion. Their conclusion was based on a retrospective non-controlled study of 39 eyes, which we believe is an inadequate study type and too small a number of eyes for such a conclusion. In our prospective, randomized, controlled study with three times the number of eyes, no fl ap adhesion complications occurred in the eyes that received apraclonidine.
There are several hypotheses regarding the topical infl uence of alpha-2 agonistic effect, such as a direct lubricant impact, a desiccation or ischemic effect of the anterior segment due to anterior ocular vessels constriction, and/or direct toxic effect to the endothelial cells. 7 However, we tend to agree with Norden 6 that a simpler reason, such as excess moisture on the bed and insuffi cient fl ap stroking, may be responsible for the poor fl ap adherence described previously.
Topical apraclonidine before LASIK surgery may prevent early postoperative hyperemia and subconjunctival hemorrhage without adverse effects on the fl ap adherence.
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Please provide the brand name (and its manufacturer and location) of apraclonidine.
Please provide the city in which TRB Chemedica is located in Greece.
The following has been changed. Okay as edited? Original: As for this statistical test, the expected frequency may not be smaller than 5 in more than 20% of cells, 8 the values for moderate and severe hyperemia were joined only for the purpose of statistical evaluation. Edited: For this statistical test, the expected frequency could not be Ͻ5 in Ͼ20% of cells, 8 therefore the values for moderate and severe hyperemia were combined for the purpose of statistical evaluation.
Please clarify the following. What might apraclonidine add? As more speculations arise from glaucoma specialists about potential barotrauma damage on the optic nerve head during suction in LASIK surgery, apraclonidine might add more in our everyday surgical routine.
The following has been rewritten. Okay as edited? Original: Since the perfusion pressure (PF) equals the systemic blood pressure (BP) minus the intraocular pressure (IOP), apraclonidine applied just 30 seconds before LASIK surgery, its vasoconstrictive effect started before vacuum ring application.
Edited: Because the perfusion pressure equals the systemic blood pressure minus the intraocular pressure (IOP), when apraclonidine is applied just 30 seconds before LASIK surgery, its vasoconstrictive effect begins prior to vacuum ring application.
